Scott S Tykodi

5PUBLICATIONS
11CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Dec 10, 2025
From surgery to systemic therapy in von Hippel-Lindau disease: insights from extended follow-up of LITESPARK-004.

Lisa M Tachiki, Scott S Tykodi

|Sep 14, 2022
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.

Daniel J George, David R Spigel, Lucio N Gordan

|May 05, 2022
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.

Timothy A Yap, Justin F Gainor, Margaret K Callahan

|Feb 25, 2022
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.

Scott S Tykodi, Lucio N Gordan, Robert S Alter

|Mar 05, 2021
Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma.

Yuexin Xu, Chris P Miller, Edus H Warren

Pageof 1

Frequent Collaborators

2 joint publications

Daniel J George

1 joint publications

Yuexin Xu

1 joint publications

Edus H Warren

1 joint publications

Timothy A Yap